Clinical Trial Update: A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A randomized Phase 2 trial of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AT-101 (gossypol acetic acid)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Ascenta Therapeutics | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED